Electronic Supplementary Material (ESI) for Lab on a Chip. This journal is © The Royal Society of Chemistry 2024

Supplementary materials

Deciphering Fibroblast-Induced Drug Resistance in Non-Small Cell Lung Carcinoma through Patient-Derived Organoids in Agarose Microwells

Qiyue Luan,¹ Ines Pulido,^{2,3} Angelique Isagirre,¹ Julian Carretero,⁴ Jian Zhou,^{1,3} Takeshi Shimamura,^{2,3} and Ian Papautsky^{1,3}*

*Address of correspondence Dr. Ian Papautsky Department of Biomedical Engineering 851 S. Morgan Street, 218 SEO University of Illinois Chicago Chicago, IL 60607, USA E-mail: papauts@uic.edu; Tel: +1 312.413.3800

¹Department of Biomedical Engineering, University of Illinois Chicago, Chicago, IL 60607, USA

²Department of Surgery, University of Illinois Chicago, Chicago, IL 60612, USA

³University of Illinois Cancer Center, Chicago, IL 60612, USA

⁴Departament de Fisiologia, Facultat de Farmacia, Universitat de Valencia, Burjassot, 46010, Spain

	Medium		WI-38-sup			NSCLC : WI-38 = 4:1			NSCLC : WI-38 = 1:1			NSCLC : WI-38 = 1:4			
		•						•		•		•	*	46	14
A549	•				a	•				•	•		**	*	
	٠		•	•		6			10_	•	•	•_	4		*
H358	9				*	*	4		16-	a	*	*	*		*
	4	*	4	*	10.	*	*		.00	4		16	100	4	椒
	-0-	推	104	*	4.	*			*	*		4	*	29	d

Figure S1. NSCLC cell lines A549 and NCI-H358 were co-cultured with fibroblasts in agarose microwells and formed tight spheroids. Scale bars: $200\mu m$.




Figure S2. The comparison of 3D cell viability evaluation methods between live/dead staining images and ATP luminescence assays. The cytotoxicity of H358 spheroids following adagrasib treatment with normal culture medium and WI-38 supernatant were analyzed by z-stack live/dead fluorescent images and ATP luminescence assays.

	A549		NCI-I	H358	WI-38		
TH01	8	9.3	6	6	8	9.3	
D21S11	29	29	28	30	30	30.2	
D5S818	11	11	10	12	10	10	
D13S317	11	11	8	12	11	11	
D7S820	8	11	10	11	9	11	
D16S539	11	12	12	13	11	12	
CSF1PO	10	12	11	12	10	12	
AMEL	Х	Υ	Х	Υ	X	Х	
vWA	14	14	17	17	19	20	
TPOX	8	11	8	9	8	8	

Table S1. STR profiles of the cell lines A549, NCI-H358, and WI-38 used in this study.

	CAF41	CAF63
Mutation	EGFR L858R	KRAS G12C
Age	48	62
Sex	Female	Male
Stage	IB	IA
Smoking status	Non-smoker	Ex-smoker

Table S2. The clinicopathological features of the patients from whom the CAF41/CAF63 were derived.